Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sarepta Therapeutics, Inc. (NASDAQ: SRPT).

Full DD Report for SRPT

You must become a subscriber to view this report.


Recent News from (NASDAQ: SRPT)

Abuse-Deterrent Opioids: A Business Answer To The Opioid Abuse Crisis
Context The widespread abuse of opioids has been a national tragedy. It has contributed to the deaths of thousands and led to billions of dollars spent in search of comprehensive remedies. To date, no single solution has been completely effective in reducing the consequences of opioid abuse,...
Source: SeekingAlpha
Date: September, 13 2018 11:41
Your Daily Scoop: Compugen's Trial Begins, Tezepelumab Designated, Sarepta's Alternatives
Stocks in the News: CEGN, AMGN Compugen's first patient dosed with COM701 in Phase 1 clinical trial Discussion : First patient is dosed in Phase 1 clinical trial of Compugen's ( CGEN )COM701 indicated as a cancer immunotherapy antibody targeting PVRIG. The safety and tolerability of t...
Source: SeekingAlpha
Date: September, 10 2018 11:32
Parent Project Muscular Dystrophy and Sarepta Therapeutics Partner to Launch Duchenne Outcomes Research Interchange, a Patient-Data Warehouse Serving the Entire Duchenne Community
HACKENSACK, N.J. and CAMBRIDGE, Mass. , Sept. 7, 2018 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced plans today to launch a patient- and physician-reported outcomes d...
Source: PR Newswire
Date: September, 07 2018 08:50
Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Nasdaq’...
Source: GlobeNewswire
Date: September, 07 2018 08:30
Premarket analyst action - healthcare
Solid Biosciences (NASDAQ: SLDB ) initiated with Neutral rating and $38 (12% downside risk) price target at Credit Suisse. More news on: Solid Biosciences, Inc., Sarepta Therapeutics, Inc., iRhythm Technologies, Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 06 2018 09:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14151.00150.21156.17146.1551,360,414
2017-02-0329.1528.9329.3428.82621,167
2017-02-0228.9128.9129.4728.401,791,274
2017-02-0130.5129.1030.8028.583,856,852
2017-01-3128.7231.0631.2928.273,766,743

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07107,356183,86858.3875Short
2018-12-06115,903276,30741.9472Short
2018-12-0482,324173,12447.5520Short
2018-12-0333,40875,35544.3342Short
2018-11-3050,808105,33248.2361Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SRPT.


About Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

Logo for Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

Not available

 

Contact Information

 

 

Current Management

  • Christopher Garabedian / President, CEO
  • Edward M. Kaye / Senior VP, Chief Med. Officer
  • Sandesh Mahatme / Senior VP, CFO, Chief Accounting Officer
  • Michael Jacobsen / VP, Fin.
  • Effie Toshav / General Counsel
  • Melinda Miles / Controller
  • Erin Cox / IR

Current Share Structure

  • Market Cap: $6,125,842,180 - 05/18/2018
  • Issue and Outstanding: 65,531,046 - 04/30/2018

 


Recent Filings from (NASDAQ: SRPT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018

 

 


Daily Technical Chart for (NASDAQ: SRPT)

Daily Technical Chart for (NASDAQ: SRPT)


Stay tuned for daily updates and more on (NASDAQ: SRPT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SRPT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SRPT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SRPT and does not buy, sell, or trade any shares of SRPT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/